A majority of the HIV-infected cells that persist in HIV-infected individuals even during suppressive antiretroviral therapy (ART) originated from cellular proliferation, not viral replication, according to new research published in Nature Communications. Reducing the population size of this “reservoir” of infected cells represents the largest challenge for cure of HIV. Based on these results, study […]Continue Reading ...
A new study reveals that Hispanic HIV-infected adults in the United States are at a higher risk of developing cancers caused by the human papillomavirus (HPV) than Hispanics from the general population. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings highlight the need for continued efforts to develop […]Continue Reading ...
Credit: pixabay By destroying the regulatory genes of the AIDS virus HIV-1 using the genome editing system CRISPR/Cas9, a Japanese research group has succeeded in blocking the production of HIV-1 by infected cells. Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by […]Continue Reading ...
July 3, 2018 Fetal death in utero occurred in more than one-fourth of monkeys infected in the laboratory with Zika virus in early pregnancy, according to new research published in Nature Medicine. The finding raises the concern that Zika virus-associated pregnancy loss in humans may be more common than currently thought, according to the study […]Continue Reading ...
By Dr Ananya Mandal, MDMay 22, 2018 At least nine individuals have died due to the deadly Nipah virus in Kerala, India. Over 25 have been infected with this virus in the outbreak say official sources. Nipah virus is a deadly virus that spread rapidly among populations and has a death rate of between 40 […]Continue Reading ...
Credit: CC0 Public Domain UC San Francisco scientists have uncovered new mechanisms by which HIV hides in infected cells, resting in a latent state that evades the body’s immune system and prevents antiviral drugs from flushing it out. The findings, published online February 28, 2018, in Science Translational Medicine, could help scientists design and test […]Continue Reading ...
August 1, 2017 Gilead Sciences, Inc. as of late introduced that the U.S. Meals and Drug Management (FDA) has authorized up to date labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the primary all-oral, pan-genotypic, once-daily unmarried pill routine (STR) for the medication of adults with power hepatitis C virus (HCV) an infection, to incorporate use in […]Continue Reading ...
A team led by Professor Arne Skerra at the Technical University of Munich (TUM) has developed an innovative strategy for preventing the anthrax bacterium from absorbing iron, which is crucial for its survival. It does so by neutralizing a special iron complexing agent produced by the bacterium. Because the anthrax pathogen only spreads in the […]Continue Reading ...
July 11, 2018 A team of scientists from The Forsyth Institute, a global leader in oral health research, in collaboration with the NIH-funded Pediatric HIV/AIDS Cohort Study (PHACS), has published the results of a new study indicating that differences in the mouth bacteria of youth born with HIV may increase their risk of cavities. The […]Continue Reading ...
HIV infecting a human cell. Credit: NIH Researchers have provided new insight into the cellular processes behind the ‘shock and kill’ approach to curing HIV, which they say challenges the effectiveness of the treatment. Their study, published in the journal eLife, suggests the need to explore alternative treatment strategies against HIV—a virus which 36.7 million […]Continue Reading ...
May 2, 2018 Researchers have provided new insight into the cellular processes behind the ‘shock and kill’ approach to curing HIV, which they say challenges the effectiveness of the treatment. Their study, published in the journal eLife, suggests the need to explore alternative treatment strategies against HIV – a virus which 36.7 million people globally […]Continue Reading ...
Tailgating may also be a laugh, however watch what is going into your drink. Credit score: Monkey Trade Photographs/www.shutterstock.com Have you ever ever thought of what would possibly tag alongside whilst you upload ice or a lemon slice in your drink? When lemons and ice are served in drinks, they no longer most effective deliver […]Continue Reading ...
August 1, 2017 Gilead Sciences, Inc. lately introduced that the U.S. Meals and Drug Management (FDA) has authorized up to date labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the primary all-oral, pan-genotypic, once-daily unmarried pill routine (STR) for the medicine of adults with power hepatitis C virus (HCV) an infection, to incorporate use in sufferers co-infected […]Continue Reading ...
- Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease
- New contact lens to treat eye injuries
- Acne could have a genetic basis find researchers promising new cure
- Higher physical activity associated with improved mood
- New UGA study points to optimal hypertension treatment for stroke patients
- Study highlights factors that can reduce food cravings
- Researchers discover Ebola-fighting protein in human cells
- Fentanyl surpasses heroin in cause of U.S. drug overdose deaths
- When Heart Attack Strikes, Women Often Hesitate to Call for Help
- A warning about costume contacts
- Study examines link between peripheral artery disease and heart attack
- Researchers develop biotechnological tool to produce antifungal proteins in plants
- 3D-printed adaptive aids can benefit patients with arthritis
- Chronic bullying during adolescence impacts mental health
- Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics
- Importance of cell cycle and cellular senescence in the placenta discovered
- Gold “nanoprisms” open new window into vessels and single cells
- Research findings could lead to new targets for cancer-fighting therapeutics
- Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines
- Study explores how patients want to discuss symptoms with doctors